Shrinking the Lymphatic Filariasis Map of Zimbabwe: Reassessing the Population Requiring Treatment Through Confirmatory Mapping

Overview

Journal Int J Infect Dis

Publisher Elsevier

Date 2025 Jan 29

PMID 39880359

Authors

Nicholas Midzi

Masceline Jenipher Mutsaka-Makuvaza

Isaac Phiri

Karen Palatio

Didier Bakajika

Honorat M Zoure

Elizabeth Juma

Molly Anderson

Rebecca Mwabvu

Moses J Bockarie

Jorge Cano

Sammy M Njenga

Affiliations

Soon will be listed here.

Abstract

Objectives: Zimbabwe is endemic for lymphatic filariasis (LF) with 39 districts identified for mass drug administration (MDA) in 2014. The objective of this study was to reassess the current population requiring MDA.

Methods: The LF confirmatory mapping method was used to evaluate the prevalence of circulating filarial antigens among school-aged children (9-14 years) in previously endemic districts. This was achieved through a cross-sectional survey between 2021 and 2023, applying a cluster sampling approach across 39 districts, targeting 18,720 children to assess ongoing LF transmission.

Results: The findings revealed a significant decline in LF prevalence, with an overall rate of 0.43%. Importantly, 82.05% of districts previously identified as endemic were reclassified as nonendemic. Only seven districts retained endemic status, necessitating continued MDA using the triple-drug therapy regimen. Population estimates based on 2022 census data indicated that 1.19 million individuals across these districts require MDA, representing an 84.4% reduction compared to previous estimates. Despite the progress, the persistence of low-level transmission in certain districts highlights the need for sustained surveillance and morbidity management services, including hydrocele surgery and lymphedema care.

Conclusion: There was a significant reduction in the number of people requiring MDA. The decline in LF endemicity is attributed to a combination of factors, including prior rounds of MDA and vector control initiatives including historical interventions, such as dichlorodiphenyltrichloroethane spraying against human African trypanosomiasis.

References

Lammie P, Gass K, King J, Deming M, Addiss D, Biswas G . Evolution of the monitoring and evaluation strategies to support the World Health Organization's Global Programme to Eliminate Lymphatic Filariasis. Int Health. 2020; 13(Suppl 1):S65-S70. PMC: 7753166. DOI: 10.1093/inthealth/ihaa084. View

Bockarie M, Rebollo M . Reducing the population requiring interventions against lymphatic filariasis in Africa. Lancet Glob Health. 2016; 4(3):e154-5. DOI: 10.1016/S2214-109X(15)00292-2. View

. Global programme to eliminate lymphatic filariasis: progress report, 2015. Wkly Epidemiol Rec. 2016; 91(39):441-55. View

Greene S, Fischer K, Choi Y, Curtis K, Budge P, Mitreva M . Characterization of a novel microfilarial antigen for diagnosis of Wuchereria bancrofti infections. PLoS Negl Trop Dis. 2022; 16(5):e0010407. PMC: 9126377. DOI: 10.1371/journal.pntd.0010407. View

. Global programme to eliminate lymphatic filariasis: progress report, 2016. Wkly Epidemiol Rec. 2017; 92(40):594-607. View

Cano J, Rebollo M, Golding N, Pullan R, Crellen T, Soler A . The global distribution and transmission limits of lymphatic filariasis: past and present. Parasit Vectors. 2014; 7:466. PMC: 4197264. DOI: 10.1186/s13071-014-0466-x. View

Dickson B, Masson J, Mayfield H, Aye K, Htwe K, Roineau M . Bayesian Network Analysis of Lymphatic Filariasis Serology from Myanmar Shows Benefit of Adding Antibody Testing to Post-MDA Surveillance. Trop Med Infect Dis. 2022; 7(7). PMC: 9323698. DOI: 10.3390/tropicalmed7070113. View

Jambulingam P, Kuttiatt V, Krishnamoorthy K, Subramanian S, Srividya A, Raju H . An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLoS Negl Trop Dis. 2021; 15(2):e0009069. PMC: 7909694. DOI: 10.1371/journal.pntd.0009069. View

Gass K, Sime H, Mwingira U, Nshala A, Chikawe M, Pelletreau S . The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania. PLoS Negl Trop Dis. 2017; 11(10):e0005944. PMC: 5643143. DOI: 10.1371/journal.pntd.0005944. View

10.

Gambhir M, Bockarie M, Tisch D, Kazura J, Remais J, Spear R . Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. BMC Biol. 2010; 8:22. PMC: 2848205. DOI: 10.1186/1741-7007-8-22. View

11.

Nsakashalo-Senkwe M, Mwase E, Chizema-Kawesha E, Mukonka V, Songolo P, Masaninga F . Significant decline in lymphatic filariasis associated with nationwide scale-up of insecticide-treated nets in Zambia. Parasite Epidemiol Control. 2018; 2(4):7-14. PMC: 5952671. DOI: 10.1016/j.parepi.2017.08.001. View

12.

King C, Weil G, Kazura J . Single-Dose Triple-Drug Therapy for - 5-Year Follow-up. N Engl J Med. 2020; 382(20):1956-1957. PMC: 7175637. DOI: 10.1056/NEJMc1914262. View

13.

Taylor M, Hoerauf A, Bockarie M . Lymphatic filariasis and onchocerciasis. Lancet. 2010; 376(9747):1175-85. DOI: 10.1016/S0140-6736(10)60586-7. View

14.

HAWKING F . The distribution of human filariasis throughout the world. Part III. Africa. Trop Dis Bull. 1977; 74(8):649-79. View

15.

Irvine M, Reimer L, Njenga S, Gunawardena S, Kelly-Hope L, Bockarie M . Modelling strategies to break transmission of lymphatic filariasis--aggregation, adherence and vector competence greatly alter elimination. Parasit Vectors. 2015; 8:547. PMC: 4618540. DOI: 10.1186/s13071-015-1152-3. View

16.

Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld M . The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial. PLoS Negl Trop Dis. 2020; 14(3):e0008106. PMC: 7098623. DOI: 10.1371/journal.pntd.0008106. View

17.

Fischer P, King C, Jacobson J, Weil G . Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. PLoS Negl Trop Dis. 2017; 11(1):e0005163. PMC: 5215784. DOI: 10.1371/journal.pntd.0005163. View

18.

. WHO position statement on integrated vector management to control malaria and lymphatic filariasis. Wkly Epidemiol Rec. 2011; 86(13):121-7. View

19.

Rebollo M, Sambou S, Thomas B, Biritwum N, Jaye M, Kelly-Hope L . Elimination of lymphatic filariasis in the Gambia. PLoS Negl Trop Dis. 2015; 9(3):e0003642. PMC: 4364952. DOI: 10.1371/journal.pntd.0003642. View

20.

Sime H, Gass K, Mekasha S, Assefa A, Woyessa A, Shafi O . Results of a confirmatory mapping tool for Lymphatic filariasis endemicity classification in areas where transmission was uncertain in Ethiopia. PLoS Negl Trop Dis. 2018; 12(3):e0006325. PMC: 5886699. DOI: 10.1371/journal.pntd.0006325. View